Huntington National Bank Purchases 135 Shares of DaVita Inc. (NYSE:DVA)

Huntington National Bank increased its holdings in DaVita Inc. (NYSE:DVA) by 17.6% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 903 shares of the company’s stock after acquiring an additional 135 shares during the period. Huntington National Bank’s holdings in DaVita were worth $135,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently modified their holdings of the company. SBI Securities Co. Ltd. bought a new position in DaVita in the 4th quarter valued at $41,000. Quarry LP bought a new position in DaVita during the third quarter valued at about $60,000. Venturi Wealth Management LLC increased its holdings in DaVita by 59.8% during the fourth quarter. Venturi Wealth Management LLC now owns 406 shares of the company’s stock worth $61,000 after buying an additional 152 shares during the last quarter. Versant Capital Management Inc raised its position in DaVita by 58.7% in the fourth quarter. Versant Capital Management Inc now owns 457 shares of the company’s stock worth $68,000 after acquiring an additional 169 shares during the period. Finally, Blue Trust Inc. grew its position in shares of DaVita by 39.7% during the 4th quarter. Blue Trust Inc. now owns 461 shares of the company’s stock valued at $76,000 after acquiring an additional 131 shares during the period. 90.12% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of equities research analysts recently commented on DVA shares. Cowen reaffirmed a “hold” rating on shares of DaVita in a report on Tuesday, February 18th. StockNews.com cut DaVita from a “buy” rating to a “hold” rating in a research report on Wednesday. Barclays lifted their price objective on DaVita from $164.00 to $169.00 and gave the stock an “equal weight” rating in a report on Tuesday, February 18th. Finally, Sanford C. Bernstein set a $184.00 price objective on shares of DaVita in a report on Friday, February 21st. One equities research analyst has rated the stock with a sell rating, five have given a hold rating and one has issued a buy rating to the stock. According to MarketBeat.com, DaVita currently has an average rating of “Hold” and a consensus target price of $166.33.

DaVita Stock Performance

Shares of DVA opened at $149.37 on Friday. DaVita Inc. has a 52-week low of $125.64 and a 52-week high of $179.60. The stock’s 50-day simple moving average is $155.75 and its 200 day simple moving average is $157.23. The company has a debt-to-equity ratio of 23.18, a quick ratio of 1.21 and a current ratio of 1.26. The stock has a market capitalization of $11.95 billion, a price-to-earnings ratio of 13.91, a price-to-earnings-growth ratio of 1.07 and a beta of 1.04.

DaVita (NYSE:DVA) last released its quarterly earnings data on Thursday, February 13th. The company reported $2.24 EPS for the quarter, beating analysts’ consensus estimates of $2.14 by $0.10. DaVita had a net margin of 7.31% and a return on equity of 115.48%. Research analysts forecast that DaVita Inc. will post 10.76 EPS for the current fiscal year.

DaVita Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.